At a glance
This program funds investigator-initiated pilot or exploratory studies on how incretin mimetics, especially GLP-1 or dual GLP-1/GIP-1 receptor agonists, may affect cancer risk. It allows new and resubmission applications from a wide range of U.S. and non-U.S. organizations, including nonprofits, universities, governments, small businesses, and foreign organizations. The budget is limited to $275,000 in direct costs over up to 2 years, with no more than $200,000 in any single year, and no cost sharing is required. Clinical trials are not allowed, and animal studies must include a cancer endpoint while human studies may use cancer biomarker endpoints linked to cancer development.
What it funds
Official description from grants.gov
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments